Common Genomic Variation in the APOC3 Promoter Associated With Variation in Plasma Lipoproteins
- 1 November 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 17 (11) , 2753-2758
- https://doi.org/10.1161/01.atv.17.11.2753
Abstract
We hypothesized that common genomic variation that affected the expression and/or function of the products of the APOC3 , APOE , FABP2 , and PON1 genes would be associated with variation in biochemical phenotypes in a previously unstudied human sample. We determined genotypes of functional genomic variants of APOC3 , APOE , FABP2 , and PON1 in 509 adult aboriginal Canadians from an isolated community in Northern Ontario. We tested for genotype associations with plasma lipoprotein traits. We found that (1) common variation at nucleotide −455 of the APOC3 promoter was associated with variation in plasma triglycerides ( P =.006) and (2) common variation of APOE determining plasma isoforms of apo E was associated with variation in plasma apo B ( P =.009). Analysis of subjects classed by APOC3 markers showed that homozygosity for presence of a C at nucleotide −455 and a T at nucleotide −482 was associated with significantly increased plasma triglycerides in both men and women. Furthermore, this allele was approximately twice as frequent in subjects within the highest quartile of plasma triglycerides as in subjects within the lowest quartile. Since the DNA variation detected by the APOC3 markers affects in vitro expression of the gene product, it is possible that the marker itself caused the associations. However, the associations could also have resulted from linkage disequilibrium with other functional variants in APOC3 or the closely linked APOA1 and/or APOA4 genes.Keywords
This publication has 17 references indexed in Scilit:
- A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease.Journal of Clinical Investigation, 1995
- Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia.Journal of Clinical Investigation, 1995
- An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance.Journal of Clinical Investigation, 1995
- Identification of a distinct human high‐density lipoprotein subspecies defined by a lipoprotein‐associated protein, K‐45European Journal of Biochemistry, 1993
- The molecular basis of the human serum paraoxonase activity polymorphismNature Genetics, 1993
- Interethnic variation of drug metabolismTrends in Pharmacological Sciences, 1991
- Hypertriglyceridemia as a Result of Human apo CII Gene Expression in Transgenic MiceScience, 1990
- Genetic basis of lipoprotein disorders.Journal of Clinical Investigation, 1989
- Deoxyribonucleic acid polymorphism in the apolipoprotein A-1-C-III gene cluster. Association with hypertriglyceridemia.Journal of Clinical Investigation, 1985
- Linkage disequilibrium in finite populationsTheoretical and Applied Genetics, 1968